[MS3] Mini Symposium 3
Allergic skin diseases

[MS3-6] Effectiveness and safety of icatibant in patients with hereditary angioedema with normal C1-INH levels: findings from the Icatibant Outcome Survey (IOS)

Anete S Grumach¹, Teresa Caballero², Marcus Maurer³, Hilary J Longhurst⁴, Andrea Zanichelli⁵, Werner Aberer⁶, Jaco Botha⁷, Irmgard Andresen⁷, Giorgio Giannattasio⁷, Laurence Bouillet⁸ (1.Clinical Immunology, Medical School, University Center Health ABC, Brazil, 2.Department of Allergy, Hospital Universitario La Paz, Biomedical Research Network on Rare Diseases (CIBERER, U754), Spain, 3.Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedízin Berlin, Germany, 4.Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, and University College London Hospitals, UK, 5.Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, ASST Fatebenefratelli Sacco, Italy, 6.Department of Dermatology and Venereology, Medical University of Graz, Austria, 7.Shire (a Takeda company), Switzerland, 8.National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University, Grenoble, France)